Dawnrays Pharmaceutical (Holdings) Ltd is an investment holding company mainly engaged in the development, manufacture and sale of non-patented drugs. The Company operates its business through two segments. The finished drugs segment is engaged in the manufacture and sale of finished drugs. The intermediates and bulk medicines segment is engaged in the manufacture and sale of intermediates and bulk medicines.

Employees

1,074

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-10-02	HK$0.9700	-0.51%	132,000
26-09-30	HK$0.9750	-0.51%	344,000
26-09-29	HK$0.9800	+0.51%	264,000
26-09-28	HK$0.9750	0.00%	112,000
26-09-25	HK$0.9750	+0.52%	112,000

Delayed Quote Hong Kong S.E.

More quotes

Market Closed - Hong Kong S.E. 04:08:09 2026-10-02 EDT			5-day change	1st Jan Change
0.9700 ^HKD	-0.51%		-0.51%	-20.49%

08-28	Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-28	Dawnrays Pharmaceutical Limited Announces Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2026, Payable on 09 October 2026	CI

Market Cap	1.25B 1.46B 186M 165M 154M 141M 265M 17.9B 268M 1.87B 724M 9.15B 699M 684M 29.37B	P/E 2024	3.06x	P/E 2025	7.83x
Enterprise Value	-479M -560M -71.42M -63.46M -59.23M -53.98M -102M -6.87B -103M -717M -278M -3.51B -268M -262M -11.26B	EV / Sales 2024	0.14x	EV / Sales 2025	-0.06x
Free-Float	32.58%	Yield 2024	5.16%	Yield 2025	5.16%

08-28	Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-28	Dawnrays Pharmaceutical Limited Announces Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2026, Payable on 09 October 2026	CI
05-29	Dawnrays Pharmaceutical Limited Announces That the Group's Subsidiary, Fujian Dawnrays Pharmaceutical Co., Ltd. Obtains Approval for Drug Production and Registration for Trazodone Hydrochloride Tablets 50Mg and 100Mg	CI
05-22	Dawnrays Pharmaceutical Limited Approves Final Dividend for the Year Ended 31 December 2025	CI
03-27	Dawnrays Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-27	Dawnrays Pharmaceutical (Holdings) final dividend of HK$0.048 per share	RE
03-27	Dawnrays Pharmaceutical Limited Proposes Final Cash Dividend for the Year Ended December 31, 2025, Payable on June 12, 2026	CI
25-08-22	Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-22	Dawnrays Pharmaceutical Limited Announces Interim Dividend for the Six Months Ended 30 June 2025, Payable on 03 October 2025	CI
25-08-22	Dawnrays pharmaceutical reports HY net income attributable of RMB104.6 mln	RE
25-07-31	Dawnrays Pharmaceutical Limited Announces Appointment of Hu Shuo as Non-Executive Director with Effect from 1 August 2025	CI
25-05-23	Dawnrays Pharmaceutical Limited Declares Final Dividend for the Year Ended 31 December 2024	CI
25-05-23	Dawnrays Pharmaceutical Limited Declares Special Dividend for the Year Ended 31 December 2024	CI

21-04-19	Dawnrays Pharmaceutical : Form of proxy for use at the Annual General Meeting of the Company to be held on Friday, 28 May 2021 (or at any adjournment thereof)	PU
21-04-19	Dawnrays Pharmaceutical : PROPOSALS FOR GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES; RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING	PU
20-09-23	Dawnrays Pharmaceutical : Next Day Disclosure Return	PU
20-09-22	Dawnrays Pharmaceutical : Next Day Disclosure Return	PU
20-09-21	Dawnrays Pharmaceutical : Next Day Disclosure Return	PU

Dawnrays Pharmaceutical (Holdings) Limited Stock

Stocks

2348

KYG2687M1006

Pharmaceuticals

Valuation: Dawnrays Pharmaceutical (Holdings) Limited

Chart: Dawnrays Pharmaceutical (Holdings) Limited

Latest news: Dawnrays Pharmaceutical (Holdings) Limited

Press Releases: Dawnrays Pharmaceutical (Holdings) Limited

Quotes and Performance

Price Extremes

Managers and Directors: Dawnrays Pharmaceutical (Holdings) Limited

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 day	-0.51%
1 week	-0.51%
Current month	-0.51%
1 month	-2.51%
3 months	-3.00%
6 months	-16.38%
Current year	-20.49%

1 week	0.96	0.98
1 month	0.96	1
Current year	0.96	1.22
1 year	0.96	1.26
3 years	0.96	1.47
5 years	0.96	1.76
10 years	0.84	2.75

Manager	Title	Age	Since
Li Wei Yu CEO	Chief Executive Officer	56	2024-09-12
Yi jun Wu DFI	Director of Finance/CFO	61	-
Michelle Li IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Kei Ling Li CHM	Chairman	77	2002-09-30
Yung Lai Hung BRD	Director/Board Member	81	2002-09-30
Hong Man Leung BRD	Director/Board Member	51	2005-10-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/23/26	Fortune United Group Ltd	Other	Company	76,000	0.0050%
9/23/26	Kei Ling Li	Other	Chairman	76,000	0.0050%
9/22/26	Kei Ling Li	Other	Chairman	92,000	0.0061%

	2024	2025
Net sales	1.06B 1.24B 158M 141M 131M 120M 225M 15.2B 228M 1.59B 615M 7.77B 594M 581M 24.94B	1.23B 1.44B 184M 163M 152M 139M 262M 17.65B 264M 1.84B 714M 9.02B 689M 674M 28.95B
Net income	565M 661M 84.26M 74.86M 69.87M 63.69M 120M 8.1B 121M 846M 328M 4.14B 316M 309M 13.29B	214M 250M 31.91M 28.35M 26.46M 24.12M 45.49M 3.07B 45.92M 320M 124M 1.57B 120M 117M 5.03B
Net Debt	-1.57B -1.84B -235M -208M -195M -177M -334M -22.55B -338M -2.35B -912M -11.53B -881M -862M -37B	-1.73B -2.02B -258M -229M -214M -195M -367M -24.77B -371M -2.59B -1B -12.66B -967M -946M -40.63B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED	-0.51%	-0.51%	-19.17%	-12.61%	186M
ELI LILLY AND COMPANY	-0.61%	-3.43%	+39.40%	+112.31%	1,019B
JOHNSON & JOHNSON	-1.02%	-5.60%	+37.67%	+65.02%	617B
ABBVIE INC.	+1.11%	-0.58%	+11.10%	+77.28%	464B
MERCK & CO., INC.	+0.34%	-3.01%	+61.21%	+40.71%	356B
ROCHE HOLDING AG	-0.95%	-4.05%	+21.60%	+39.37%	333B
NOVARTIS AG	-1.46%	-2.89%	+11.84%	+24.60%	267B
ASTRAZENECA PLC	-1.35%	-5.43%	-4.69%	+8.40%	244B
AMGEN INC.	-1.04%	-2.79%	+35.52%	+51.34%	218B
GILEAD SCIENCES, INC.	-1.87%	-4.10%	+30.92%	+95.33%	179B
Average	-0.26%	-3.10%	+22.54%	+50.18%	369.74B
Weighted average by Cap.	+0.42%	-3.33%	+30.51%	+68.95%